Trial Profile
Memantine and cognitive dysfunction in bipolar disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2017
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Bipolar disorders
- Focus Therapeutic Use
- 26 Mar 2012 Actual patient number (47) added as reported by ClinicalTrials.gov.
- 26 Mar 2012 Actual end date Jun 2010 added as reported by ClinicalTrials.gov.
- 26 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.